Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: A biomarker approach using N-terminal proBNP

Heart

Volumn 96, Issue 11, 2010, Pages 831-837

  Squire, Iain ^a   Quinn, Paulene ^a   Narayan, Hafid ^a   Khan, Sohail ^a   Dhillon, Onkar ^a   Ng, Kuan ^a   Kelly, Dominic ^a   Davies, Joan ^a   Ng, Leong ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY CARE UNIT; DEATH; DEMOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK REDUCTION; SCORING SYSTEM; ST SEGMENT ELEVATION; TEACHING HOSPITAL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; YOUNG ADULT;

EID: 77953716213     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.184614     Document Type: Article

References (25)

1. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
2. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
3. Freemantle N, Cleland J, Young P, et al. β blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7. (Pubitemid 29290470)
4. Newby LK, Kristiansson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287:3087-95.
5. Pfeffer M, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
6. The Acute Infarction Ramipril Efficacy (AIRE) Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
7. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
8. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on a 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
9. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345;669-85.
10. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- convertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
11. Chinese Cardiac Study. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
12. Cleland JGF. ACE inhibitors for myocardial infarction how should they be used? Eur Heart J 1995;16:153-9.
13. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
14. The PEACE trial investigators. Angiotensin converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
15. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
16. Antman E, Anbe DT, Armstrong PW, et al. Management of patients with STEMI; Executive Summary. J Am Coll Cardiol 2004:44:671-719.
17. The task force for the diagnosis and treatment of non ST segment elevation acute coronary syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non ST segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
18. Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology; American Heart Association. Committee on the management of patients with unstable angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
19. National Institute for Health and Clinical Excellence. Clinical guideline 48: MI secondary prevention: NICE 2007.
20. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
21. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
22. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and longterm mortality in acute coronary syndromes. Circulation 2002;106:2913-18.
23. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
24. Udelson JE. The inaugural issue of circulation heart failure. Circulation Heart Failure 2008;1:1.
25. Omland T, Sabatine MS, Jablonski JA, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease. The PEACE trial. J Am Coll Cardiol 2007;50:205-14.